QUIDEL CORP /DE/
quidelortho.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 5, 2022. Its latest SEC filing is a 15-12G from Jun 6, 2022.
10-Q for Q1 FY2022, filed May 5, 2022
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Develops, manufactures and sells rapid diagnostic tests and analyzers for clinics and hospitals, laboratories, and retail and home users.
10-K for FY2021, filed Feb 18, 2022Our primary mission is to advance diagnostics to improve human health. We have a leadership position in the development, manufacturing and…View ↗
Our diagnostic testing solutions are separated into our four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular…View ↗
QuickVue. QuickVue is the brand name for our rapid, visually-read, lateral flow immunoassay products. We have been a leader in the…View ↗
Who Were Their Customers?
Healthcare providers and laboratories buy directly or through distributors; Quidel’s sales force works with distributors in point-of-care markets and directly serves hospital and reference laboratories for cell-culture tests. Retail and online outlets carry its at-home tests.
10-K for FY2021, filed Feb 18, 2022Our primary mission is to advance diagnostics to improve human health. We have a leadership position in the development, manufacturing and…View ↗
Our current business strategy is designed to serve the continuum of healthcare delivery needs globally, starting with POC clinicians…View ↗
Our North America distribution strategy takes into account the highly fragmented POC market, with many small or medium-sized customers. To…View ↗
The sales, distribution and service of our cell culture tests are controlled primarily by us. We reach laboratory end-users in hospitals…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2022, filed May 5, 2022
$479.9MView ↗
- ▲ +169%
- vs $178.1M in Q1 FY2021
-
May 6, 2022
Shareholder lawsuits seek to block planned combination
Two lawsuits allege omissions in merger disclosures and seek to prevent the combination from closing.
Sources
8-K, filed May 6, 2022
As previously disclosed in the Registration Statement, a lawsuit was filed by and purportedly on behalf of an alleged Company stockholder…View ↗
At-home testing
The latest report adds individual, non-professional buyers and home testing, with retail and online outlets as sales channels; the older report described products for professional use.
10-K for FY2018, filed Feb 15, 2019 10-K for FY2021, filed Feb 18, 2022We have a leadership position in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic…View ↗
Who Did They Compete With?
Competes with Abbott, Beckman Coulter, Thermo Fisher Scientific, Becton Dickinson, Meridian Bioscience, and Danaher
10-K for FY2021, filed Feb 18, 2022Many of our current and prospective commercial competitors, including several large pharmaceutical and diversified healthcare companies…View ↗
Loading...
